image 1
image 3
image 4
image 6
image 2
image 5
image 8
image 7

The Rappaport Institute looks forward to continuing to make substantial future contributions in biomedical research"

Professor Karl Skorecki

Technologies

Disease AreasBiopharmaceuticalMedical DevicesMedical DiagnosticsPersonalized TechnologiesBio Research ToolsOthers
 
Home » Media Center » Press Releases » 2014
Press Releases
|

2014

1 September, 2014 BioRap licensed the Heparanase project to HepaRx
FutuRx.pdf: (494.8 Kb)Download
1 April, 2014 Fairjourney Biologics, BioRap Technologies and Hadasit Medical Research Services and Development Ltd. collaborate to discover therapeutic antibodies that modulate Heparanase, a validated target for cancer therapy
17 February, 2014 BioRap Technologies Ltd. to collaborate with GlaxoSmithKline on the development of novel immunomodulator for therapy of Graft Vs host diseases (GVHD) and autoimmune diseases
BioRap Technologies Ltd. to collaborate with GlaxoSmithKline on the development of novel immunomodulator for therapy of Graft Vs host diseases (GVHD) and autoimmune diseases: (194.2 Kb)Download
גלקסו-סמית''-קליין וביוראפ חתמו על הסכם לפיתוח תרופה למניעת דחיית שתלים ולטיפול במחלות אוטואימוניות: (179.6 Kb)Download

Haptoglobin Typing

Report an Invention

For BioRap InventorsFunding Opportunities

Rappaport Institute

The Rappaport InstituteNobel Prize
Copyright © 2014 BioRap Technologies LTD. All Rights Reserved. Created by Catom web design